Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial

BACKGROUND: Anti-angiogenic therapies are effective in metastatic renal cell carcinoma (mRCC), but resistance is inevitable. A dual-inhibition strategy focused on hypoxia-inducible factor (HIF) is hypothesized to be active in this refractory setting. CRLX101 is an investigational camptothecin-contai...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Keefe, S. M., Hoffman-Censits, J., Cohen, R. B., Mamtani, R., Heitjan, D., Eliasof, S., Nixon, A., Turnbull, B., Garmey, E. G., Gunnarsson, O., Waliki, M., Ciconte, J., Jayaraman, L., Senderowicz, A., Tellez, A. B., Hennessy, M., Piscitelli, A., Vaughn, D., Smith, A., Haas, N. B.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2016
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4959924/
https://ncbi.nlm.nih.gov/pubmed/27457310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw188
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados